Literature DB >> 28107209

Nephropathic cystinosis: an update.

Koenraad R Veys1, Mohamed A Elmonem, Fanny O Arcolino, Lambertus van den Heuvel, Elena Levtchenko.   

Abstract

PURPOSE OF REVIEW: Over the past few decades, cystinosis, a rare lysosomal storage disorder, has evolved into a treatable metabolic disease. The increasing understanding of its pathophysiology has made cystinosis a prototype disease, delivering new insights into several fundamental biochemical and cellular processes. RECENT
FINDINGS: In this review, we aim to provide an overview of the latest advances in the pathogenetic, clinical, and therapeutic aspects of cystinosis.
SUMMARY: The development of alternative therapeutic monitoring strategies and new systemic and ocular cysteamine formulations might improve outcome of cystinosis patients in the near future. With the dawn of stem cell based therapy and new emerging gene-editing technologies, novel tools have become available in the search for a cure for cystinosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28107209     DOI: 10.1097/MOP.0000000000000462

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  12 in total

1.  A case with kidney transplant and cystinosis: Answers.

Authors:  Tülay Becerir; İlknur Girişgen; Neslihan Yılmaz; Olcay Güngör; Emine Şeker Ün; Ergin Sağtaş; Selçuk Yüksel
Journal:  Pediatr Nephrol       Date:  2021-03-17       Impact factor: 3.714

2.  A breakthrough in readthrough? Could geneticin lead the way to effective treatment for cystinosis nonsense mutations?

Authors:  Julian Midgley
Journal:  Pediatr Nephrol       Date:  2019-01-08       Impact factor: 3.714

3.  Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23.

Authors:  Pablo Florenzano; Macarena Jimenez; Carlos R Ferreira; Galina Nesterova; Mary Scott Roberts; Sri Harsha Tella; Luis Fernandez de Castro; Rachel I Gafni; Myles Wolf; Harald Jüppner; Barbara Gales; Katherine Wesseling-Perry; Daniela Markovich; William A Gahl; Isidro B Salusky; Michael T Collins
Journal:  J Am Soc Nephrol       Date:  2020-07-06       Impact factor: 10.121

4.  Cystinosis induced by CTNS gene mutation: a rare disease study.

Authors:  Xin Wang; Bi-Li Zhang; Xiao-Ying Chen; Zhen Guo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-12-15

5.  Clinical and neurophysiological characterization of early neuromuscular involvement in children and adolescents with nephropathic cystinosis.

Authors:  Nour Elkhateeb; Rasha Selim; Neveen A Soliman; Fatma M Atia; Ihab Ibrahim Abouelwoun; Mohamed A Elmonem; Rasha Helmy
Journal:  Pediatr Nephrol       Date:  2021-11-18       Impact factor: 3.651

Review 6.  Lysosomal storage diseases.

Authors:  Frances M Platt; Alessandra d'Azzo; Beverly L Davidson; Elizabeth F Neufeld; Cynthia J Tifft
Journal:  Nat Rev Dis Primers       Date:  2018-10-01       Impact factor: 52.329

7.  Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease.

Authors:  Sören Bäumner; Lutz T Weber
Journal:  Front Pediatr       Date:  2018-03-14       Impact factor: 3.418

8.  The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series.

Authors:  Susmito Biswas; Krishanthy Sornalingam
Journal:  Ophthalmol Ther       Date:  2018-12-05

9.  Drug Repurposing in Rare Diseases: An Integrative Study of Drug Screening and Transcriptomic Analysis in Nephropathic Cystinosis.

Authors:  Francesco Bellomo; Ester De Leo; Anna Taranta; Laura Giaquinto; Gianna Di Giovamberardino; Sandro Montefusco; Laura Rita Rega; Anna Pastore; Diego Luis Medina; Diego Di Bernardo; Maria Antonietta De Matteis; Francesco Emma
Journal:  Int J Mol Sci       Date:  2021-11-27       Impact factor: 5.923

Review 10.  Nephropathic Cystinosis: Pathogenic Roles of Inflammation and Potential for New Therapies.

Authors:  Mohamed A Elmonem; Koenraad R P Veys; Giusi Prencipe
Journal:  Cells       Date:  2022-01-06       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.